Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fujingshu is a Traditional Chinese Medicine (TCM) formulation developed by Xi'an Tianrui Pharmaceutical Development Co., Ltd., specifically indicated for the treatment of chronic pelvic inflammatory disease (CPID). It is also utilized in the management of other gynecological inflammatory conditions such as vaginitis and cervicitis. The product is typically available as an oral capsule or a vaginal effervescent tablet. Its composition includes several botanical extracts, most notably *Sophora flavescens*, *Phellodendron amurense*, and *Cnidium monnieri*, which are recognized in TCM for their ability to clear heat, dry dampness, and resolve toxins. These pharmacological actions translate to anti-inflammatory, analgesic, and antimicrobial effects that help alleviate the symptoms of pelvic inflammation and associated reproductive tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fujingshu.